原著論文

欧文

1. Uchiyama M, Maesawa C, Yashima A, Itabashi T, Ishida Y and Masuda T. Consensus primers for detecting monoclonal immunoglobulin heavy chain rearrangement in B cell lymphomas. J Clin Pathol. 56(12):978, 2003. (IF:2.5, 2023)
2. Yashima A, Maesawa C, Uchiyama M, Tarusawa M, Satoh T, Satoh M, Enomoto S, Sugawara K, Numaoka H, Murai K, Utsugisawa T, Ishida Y and Masuda T. Quantitative assessment of contaminating tumor cells in autologous peripheral blood stem cells of B-cell non-Hodgkin lymphomas using immunoglobulin heavy chain gene allele-specific oligonucleotide real-time quantitative-polymerase chain reaction. Leuk Res. 27(10):925-934, 2003. (IF:2.1, 2023)
3. Uchiyama M, Maesawa C, Yashima A, Tarusawa M, Satoh T, Ishida Y, Ito S, Murai K, Enomoto S, Utsugisawa T, Motoyoshi K and Masuda T. Development of consensus fluorogenically labeled probes of the immunoglobulin heavy-chain gene for detecting minimal residual disease in B-cell non-Hodgkin lymphomas. Cancer Sci. 94(10):877-885, 2003. (IF:4.5, 2023)
4. Uchiyama M, Maesawa C, Yashima A, Itabashi T, Satoh T, Tarusawa M, Endo M, Takahashi Y, Sasaki S, Tsuchiya S, Ishida Y and Masuda T. Development of immunoglobulin variable heavy chain gene consensus probes with conjugated 3’ minor groove binder groups for monitoring minimal residual disease in childhood acute lymphoblastic leukemia. J Clin Pathol. 56(12):952-955, 2003. (IF:2.5, 2023)
5. Uchiyama M, Maesawa C, Yashima-Abo A, Tarusawa M, Satoh M, Satoh T, Ishida Y, Ito S, Murai K, Enomoto S, Utsugisawa T and Masuda T. Short consensus probes with 3’-minor groove binder of the immunoglobulin heavy-chain gene for real-time quantitative PCR in B-cell non-Hodgkin lymphomas. Labo Invest. 84(7):932-936, 2004. (IF:5.1, 2023)
6. Itabashi T, Maesawa C, Uchiyama M, Higuchi T, Masuda T. Quantitative detection of mutant alleles of the K-ras gene with minor groove binder-conjugated fluorogenic DNA probes. Int J Oncol. 24(3):687-696, 2004. (IF:4.5, 2023)
7. Ooi J, Iseki T, Takahashi S, Tomonari A, Takasugi K, Uchiyama M, Konuma T, Futami M, Nomura A, Nakayama S, Soda Y, Ohno N, Nagamura F, Uchimaru K, Tojo A, Tani K, Asano S. Unrelated cord blood transplantation after myeloablative conditioning in patients over the age of 45 years. Br J Haematol. 126(5):711-714, 2004. (IF:5.1, 2023)
8. Uchiyama M, Maesawa C, Yashima-Abo A, Tarusawa M, Endo M, Sugawara W, Chida S, Onodera S, Tsukushi Y, Ishida Y, Tsuchiya S and Masuda T. Consensus JH Gene Probes with Conjugated 3’-Minor Groove Binder for Monitoring Minimal Residual Disease in Acute Lymphoblastic Leukemia. J Mol Diagn.7(1):121-126, 2005. (IF:3.4, 2023)
9. Ooi J, Iseki T, Takahashi S, Tomonari A, Takasugi K, Uchiyama M, Konuma T, Fukuno K, Soda Y, Ohno N, Nagamura F, Uchimaru K, Tojo A, Asano S. Unrelated cord blood transplantation after myeloablative conditioning for adult patients with refractory anemia. Int J Hematol. 81(5):424-427, 2005. (IF:1.7, 2023)
10. Tomonari A, Takahashi S, Ooi J, Iseki T, Takasugi K, Uchiyama M, Konuma T, Futami M, Ohno N, Uchimaru K, Tojo A, Asano S. Human herpesvirus 6 variant B infection in adult patients after unrelated cord blood transplantation. Int J Hematol. 81(4):352-355, 2005.(IF:1.7, 2023)
11. Tomonari A, Takahashi S, Ooi J, Nakaoka T, Takasugi K, Uchiyama M, Tsukada N, Konuma T, Iseki T, Tojo A, Asano S.Cord blood transplantation for acute myelogenous leukemia using a conditioning regimen consisting of granulocyte colony-stimulating factor-combined high-dose cytarabine, fludarabine, and total body irradiation. Eur J Haematol. 77(1):46-50, 2006. (IF:2.3, 2023)
12. Konuma T, Ooi J, Takahashi S,Tomonari A, Uchiyama M, Fukuno K, Tsukada N, Iseki T, Tojo A, Asano S. Unrelated cord blood transplantation after myeloablative conditioning in patients with acute leukemia aged between 50 and 55 years. Bone Marrow Transplant. 37(8):803-804, 2006. (IF:4.5, 2023)
13. Fukuno K, Tomonari A, Tsukada N, Takahashi S, Ooi J, Tomonari A, Konuma T, Uchiyama M, Fujii T, Endo T, Iwamoto A, Oyaizu N, Nakata K, Moriwaki H, Tojo A, Asano S. Successful cord blood transplantation for myelodysplastic syndrome resulting in resolution of pulmonary alveolar proteinosis. Bone Marrow Transplant. 38(8):581-582, 2006. (IF:4.5, 2023)
14. Takahashi S, Ooi J, Tomonari A, Konuma T, Tsukada N, Oiwa-Monna M, Fukuno K, Uchiyama M, Takasugi K, Iseki T, Tojo A, Yamaguchi T, Asano S. Comparative single-institute analysis of cord blood transplantation from unrelated donors with bone marrow or peripheral blood stem cell transplantation from related donors in adult patients with hematological malignancies after myeloablative conditioning regimen. Blood. 109 (3): 1322-1330, 2007. (IF:21.0, 2023)
15. Uchiyama M, Ikeda T. Low-dose acyclovir against reactivation of varicella zoster virus after unrelated cord blood transplantation. Int J Infect Dis. 14(5):e451-e452, 2010. (IF:4.8, 2023)
16. Sato K, Uchiyama M. Efficacy of liposomal amphotericin B after visualization of specific findings of invasive pulmonary fungal infection on CT in patients with hematologic malignancies. Suwa Red Cross Medical Journal. 6:40-44, 2012.
17. Handa T, Nishida A, Uchiyama M, Nakatsue T, Baba M, Inoue Y, Ichiwata T, Takada T, Akira M, Hebisawa A, Yoshizawa A, Ikezoe K, Hamano E, Nagai S, Mishima M, Goto H, Nakata K, Ishii H. Clinical features common to five cases with secondary pulmonary alveolar proteinosis complicated with Bechet disease. ERJ. 40: 4526, 2012. (IF:16.6, 2023)
18. Iriyama N, Kazuteru O, Hashino S, Kimura S, Nakaseko C, Takano H, Hino M, Uchiyama M, Morita S, Sakamoto J, Sakamaki H, Inokuchi K. The Efficacy of Reduced-dose Dasatinib as a Subsequent Therapy in Patients with Chronic Myeloid Leukemia in the Chronic Phase: The LD-CML Study of the Kanto CML Study Group. Intern Med. 57(1):17-23, 2018. (IF:1.0, 2023)
19. Matsue K, Kumagai K, Sugiura I, Ishikawa T, Igarashi T, Sato T, Uchiyama M, Miyamoto T, Ono T, Ueda Y, Kiguchi T, Sunaga Y, Sasaki T, Suzuki K. Correction to: Plerixafor for mobilization and collection of haematopoietic stem cells for autologous transplantation in Japanese patients with non-Hodgkin lymphoma: a randomized phase 2 study. Int J Hematol. 108(5):564, 2018. (IF:1.7, 2023)
20. Matsue K, Kumagai K, Sugiura I, Ishikawa T, Igarashi T, Sato T, Uchiyama M, Miyamoto T, Ono T, Ueda Y, Kiguchi T, Sunaga Y, Sasaki T, Suzuki K. Plerixafor for mobilization and collection of haematopoietic stem cells for autologous transplantation in Japanese patients with non-Hodgkin lymphoma: a randomized phase 2 study. Int J Hematol. 108(5):524-534, 2018. (IF:1.7, 2023)
21. Ishiyama K, Nakao S, Usuki K, Yonemura Y, Ikezoe T, Uchiyama M, Mori Y, Fukuda T, Okada M, Fujiwara SI, Noji H, Rottinghaus S, Aguzzi R, Yokosawa J, Nishimura JI, Kanakura Y, Okamoto S. Results from multinational phase 3 studies of ravulizumab (ALXN1210) versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria: subgroup analysis of Japanese patients Int J Hematol. 112(4):466-476, 2020. (IF:1.7, 2023)
22. Sunami K, Suzuki K, Ri M, Matsumoto M, Shimazaki C, Asaoku H, Shibayama H, Ishizawa K, Takamatsu H, Ikeda T, Maruyama D, Kaneko H, Uchiyama M, Kiguchi T, Iyama S, Murakami H, Takahashi K, Tada K, Macé S, Guillemin-Paveau H, Iida S. Isatuximab monotherapy in relapsed/refractory multiple myeloma: A Japanese, multicenter, phase 1/2, safety and efficacy study. Cancer Sci. 111(12):4526-4539, 2020. (IF:4.5, 2023)
23. Sunami K, Ikeda T, Huang SY, Wang MC, Koh Y, Min CK, Yeh SP, Matsumoto M, Uchiyama M, Iyama S, Shimazaki C, Lee JH, Kim K, Kaneko H, Kim JS, Lin TL, Campana F, Tada K, Iida S, Suzuki K; ICARIA-MM study group. Isatuximab-Pomalidomide-Dexamethasone Versus Pomalidomide-Dexamethasone in East Asian Patients With Relapsed/Refractory Multiple Myeloma: ICARIA-MM Subgroup Analysis. Clin Lymphoma Myeloma Leuk. 22(8):e751-e761, 2022. (IF:2.7, 2023)
24. Ishida T, Ito S, Tanaka J, Uchiyama M, Kawano Y, Moreau P, Martin T, Risse ML, Tada K, Suzuki K, Ishizawa K. Jpn Isatuximab plus carfilzomib and dexamethasone in Japanese patients with relapsed multiple myeloma: subgroup analysis of the randomized, open label, phase 3 IKEMA study. J Clin Oncol. 52(12):1446-1449, 2022. (IF:42.1, 2023)
25. Sunami K, Fuchida SI, Suzuki K, Ri M, Matsumoto M, Shimazaki C, Asaoku H, Shibayama H, Ishizawa K, Takamatsu H, Ikeda T, Maruyama D, Imada K, Uchiyama M, Kiguchi T, Iyama S, Murakami H, Onishi R, Tada K, Iida S. Anti-CD38 antibody isatuximab monotherapy for Japanese individuals with relapsed/refractory multiple myeloma: An update of the phase 1/2 ISLANDs study. Hematol Oncol. 41(3):442-452, 2023. (IF:3.3, 2023)
26. Kikuchi J, Kodama N, Takeshita M, Ikeda S, Kobayashi T, Kuroda Y, Uchiyama M, Osada N, Bogen B, Yasui H, Takahashi N, Miwa A, Furukawa Y. EMD originates from hyaluronan-induced homophilic interactions of CD44 variant-expressing MM cells under shear stress. Blood Adv. 7(4):508-524, 2023. (IF:7.4, 2023)
27. Kawano Y, Kim K, Min C K, Koh Y, Ishizawa K, Kim S H, Ito S, Tanaka J, Uchiyama M, Ishida T, Kim J S, Moreau P, Martin T, Tada K, Risse M-L, Suzuki K. Isatuximab Plus Carfilzomib and Dexamethasone in East Asian Patients With Relapsed Multiple Myeloma: Updated IKEMA Subgroup Analysis. Clin Lymphoma Myeloma Leuk. 23(10):e360-e367, 2023. (IF:2.7, 2023)
28. Kiguchi T, Hiramatsu Y, Ota S, Uchiyama M, Matsuo M, Okamura M,  Morimoto S, Tanizawa Y, Tajimi M, Payakachat N. Patient perspectives on treatment for mantle cell lymphoma and chronic lymphocytic leukemia in Japan. J Clin Exp Hematop. 64(2):119-128, 2024. (IF:0.9, 2023)
29. Peffault de Latour R, Röth A, Kulasekararaj AG, Han B, Scheinberg P, Maciejewski JP, Ueda Y, de Castro CM, Di Bona E, Fu R, Zhang L, Griffin M, Langemeijer SMC, Panse J, Schrezenmeier H, Barcellini W, Mauad VAQ, Schafhausen P, Tavitian S, Beggiato E, Chew LP, Gaya A, Huang WH, Jang JH, Kitawaki T, Kutlar A, Notaro R, Pullarkat V, Schubert J, Terriou L, Uchiyama M, Wong Lee Lee L, Yap ES, Sicre de Fontbrune F, Marano L, Alashkar F, Gandhi S, Trikha R, Yang C, Liu H, Kelly RJ, Höchsmann B, Kerloeguen C, Banerjee P, Levitch R, Kumar R, Wang Z, Thorburn C, Maitra S, Li S, Verles A, Dahlke M, Risitano AMOral Iptacopan Monotherapy in Paroxysmal Nocturnal Hemoglobinuria. N Engl J Med. 390(11):994-1008, 2024. (IF:96.2, 2023)
30. Tagami N, Uchiyiama M, Suzuki K, Shirai H, Seto T, Nishina S, Iida S. Isatuximab plus pomalidomide-dexamethasone in relapsed/refractory multiple myeloma: post-marketing surveillance in Japan. Int J Hematol. 120:217-218, 2024. (IF:1.7, 2023) .

症例報告
欧文

1. Uchiyama M, Matsumoto M, Shimokawa K, Murashima N, Hayashi T.. Idiopathic thrombocytopenic purpura associated with Helicobacter pylori infection in a patient with liver cirrhosis accompanying hepatitis B. Int J Infect Dis. 11(5):466-467, 2007. (IF:4.8, 2023)
2. Uchiyama M, Nagao T, Hattori A, Fujii T, Ichiwata T, Nakata K, Tani K, Hayashi T. Pulmonary alveolar proteinosis in a patient with Behcet’s disease. Respirology. 14(2):305-308, 2008. (IF:6.6, 2023)
3. Uchiyama M, Ikeda T. Pulmonary involvement in systemic Hodgkin’s disease. Intern Med. 48(17):1563-1564, 2009. (IF:1.0, 2023)
4. Uchiyama M, Watanabe R, Ito I, Ikeda T. Thyroid involvement in pulmonary langerhans cell histiocytosis. Intern Med. 48(23):2047-2048, 2009. (IF:1.0, 2023)
5. Uchiyama M, Hattori A, Tanaka T, Miyaji T, Matsuki Y, Fujii T, Ichiwata T, Hayashi T, Ikeda T. Acute idiopathic thrombocytopenic purpura complicated with diffuse alveolar hemorrhage in an elderly patient. Intern Med. 48(16):1449-1452, 2009. (IF:1.0, 2023)
6. Uchiyama M, Ikeda T. Successful imatinib mesylate therapy for acquired von Willebrand syndrome in chronic myelogenous leukemia. Leuk Res. 33(12):1723-1724, 2009. (IF:2.1, 2023)
7. Uchiyama M, Ikeda T.. Successful engraftment following umbilical cord blood transplantation for patients with HLA antibody with or without corresponding HLA in the transplanted cord blood. Bone Marrow Transplant. 45(1):199-200, 2010. (IF:4.5, 2023)
8. Uchiyama M, Ikeda T. Unusual presentation of serum markers for suspected Pneumocystis jiroveci pneumonia in a patient with diffuse large B-cell lymphoma. Int J Infect Dis. 14(3):e267-e268, 2010. (IF:4.8, 2023)
9. Uchiyama M, Tamai Y, Ikeda T. Entecavir as prophylaxis against HBV reactivation following chemotherapy for lymphoma. Int J Infect Dis. 14(3):e265-e266, 2010. (IF:4.8, 2023)
10. Uchiyama M, Ikeda T..Diffuse alveolar hemorrhage following unrelated cord blood transplantation. Bone Marrow Transplant. 45(4):789-790, 2010. (IF:4.5, 2023)
11. Uchiyama M, Sato K, Ikeda T. Diffuse Large B-cell Lymphoma Complicated with Autoimmune Thrombocytopenia. Intern Med. 50(11):1215-1218, 2011. (IF:1.0, 2023)
12. Sato K, Uchiyama M. Lymphadenopathy and hepatosplenomegaly in a patient with acute myelogenous leukemia. BMJ Case Rep. 2011:bcr1020114997, 2011. (IF:0.6,2023)
13. Sato K, Uchiyama M. Early radiological findings on CT in a patient with enteropathy-associated T-cell lymphoma. BMJ Case Rep. 2011:bcr1020115025, 2011. (IF:0.6,2023)
14. Sato K, Uchiyama M. Pseudohyperkalemia in acute myelogenous leukemia. Suwa Red Cross Medical Journal. 6:53-55, 2012.
15. Sato K, Uchiyama M. Isolated central nervous system relapse in a patient with diffuse large B-cell lymphoma. BMJ Case Rep. 2012 bcr.12.2011.5275, 2012. (IF:0.6,2023)
16. Sato K, Uchiyama M. Corynebacterium jeikeium bacteraemia and pulmonary infiltrates in a patient with acute myelogenous leukaemia. BMJ Case Rep. 2012:bcr1120115097, 2012. (IF:0.6,2023)
17. Uchiyama M. Invasive pulmonary aspergillosis diagnosed by broncho-alveolar lavage. BMJ Case Rep. 2012:bcr0320126144, 2012. (IF:0.6,2023)
18. Takei T, Uchiyama M. Diffuse large B-cell lymphoma with involvement of the kidney. BMJ Case Rep. 2012:bcr2012006281, 2012. (IF:0.6,2023)
19. Takei T, Uchiyama M. Primary ovarian non-Hodgkin’s lymphoma. BMJ Case Rep. 2013:bcr20132004292013, 2013. (IF:0.6,2023)
20. Hashimoto R, Uchiyama M, Maeno T. Case report of subcutaneous panniculitis-like T-cell lymphoma complicated by eyelid swelling. BMC Ophthalmol. 16:117, 2016. (IF:1.7,2023)

学会発表
教育講演

1. 内山倫宏: 多発性骨髄腫治療におけるパラダイムシフト．第27回日本医療薬学会年会，千葉,2017,11．

コーポレートセミナー

1. 内山倫宏: 全身状態管理から始まる多発性骨髄腫治療．第80回日本血液学会学術集会，大阪,2018,10.
2. 内山倫宏: 造血器腫瘍患者における感染症管理Update．第81回日本血液学会学術集会，東京,2019,10.
3. 内山倫宏: PTCL治療のポイント．第83回日本血液学会学術集会，web,2021,9.
4. 内山倫宏: 造血器腫瘍患者における真菌症管理Update．第19回日本血液学会甲信越地方会，山梨,2023,7.
5. 内山倫宏: リアルワールドで求められるPTCL治療戦略～各薬剤の特徴を最大限に活かすには～．第19回日本血液学会甲信越地方会，山梨,2023,7.